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Abstract
We are reporting qualitative and quantitative changes of the extracellular matrix (ECM) and associated receptor proteomes,
occurring during the transition from liver fibrosis and steatohepatitis to hepatocellular carcinoma (HCC). We compared two
mouse models relevant to human HCC: PDGFC transgenic (Tg) and Pten null mice, models of disease progression from
fibrosis and steatohepatitis to HCC. Using mass spectrometry, we identified in the liver of both models proteins for 26
collagen-encoding genes, providing the first evidence of expression at the protein level for 16 collagens. We also identified
post-transcriptional protein variants for six collagens and lysine hydroxylation modifications for 14 collagens. Tumor-
associated collagen proteomes were similar in both models with increased expression of collagens type IV, VI, VII, X, XIV, XV,
XVI, and XVIII. Splice variants for Col4a2, Col6a2, Col6a3 were co-upregulated while only the short form of Col18a1 increased
in the tumors. We also identified tumor specific increases of nidogen 1, decorin, perlecan, and of six laminin subunits. The
changes in these non-collagenous ECM proteins were similar in both models with the exception of laminin b3, detected
specifically in the Pten null tumors. Pdgfa and Pdgfc mRNA expression was increased in the Pten null liver, a possible
mechanism for the similarity in ECM composition observed in the tumors of both models. In contrast and besides the strong
up-regulation of integrin a5 protein observed in the liver tumors of both models, the expression of the six other integrins
identified was specific to each model, with integrins a2b, a3, a6, and b1 up-regulated in Pten null tumors and integrins a8
and b5 up-regulated in the PDGFC Tg tumors. In conclusion, HCC–associated ECM proteins and ECM–integrin networks,
common or specific to HCC subtypes, were identified, providing a unique foundation to using ECM composition for HCC
classification, diagnosis, prevention, or treatment.
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Introduction
Cirrhosis, the result of end-stage fibrosis, and steatohepatitis are
common pre-neoplastic conditions associated with hepatocarcin-
ogenesis [1]. It is therefore important to understand the
mechanisms leading to the transition from fibrosis and steatosis
to HCC. Mice with liver-specific transgenic (Tg) expression of
platelet-derived growth factor-C (PDGFC) represent a relevant
model for such a study as members of the PDGF family play major
roles in angiogenesis and fibrosis [2,3]. Moreover, these mice
develop liver fibrosis resembling human alcoholic and nonalco-
holic fatty liver disease, which precedes development of HCC
[4,5]. Another relevant model is mice with liver specific deletion of
the phosphoinositide 3-kinase (PI3K)/phosphatase and tensin
homolog (Pten). PTEN loss of function in hepatocytes leads to
steatohepatitis, fibrosis and HCC later in life [6,7]. While the liver
tumors in PDGFC Tg mice show characteristics of HCC, the
tumors in the Pten null model present a mixed phenotype of HCC
and cholangiocarcinoma [8,9]. Up to 40% of human HCCs
potentially arise from progenitor-like tumor initiating cells and
tend to have a more aggressive phenotype [10]. In addition, the
presence of intermediate cells co-expressing both hepatocyte and
biliary markers is associated with HCC occurrence [11] and
acquisition of cholangiocarcinoma-like expression traits plays a
critical role in the heterogeneous progression of HCC [12]. It is
therefore of particular relevance to compare liver proteome
changes in both the PDGFC Tg and the Pten null models.
Through mass-spectrometry-based profiling of the liver tissues
collected at different disease stages in these two mouse models, we
have characterized changes in the liver proteome occurring in
fibrotic and steatotic tissue, as well as in tumors. We previously
reported that the extensive mass-spectrometry-based approach we
PLoS Genetics | www.plosgenetics.org 1 June 2011 | Volume 7 | Issue 6 | e1002147used in this study reaches depth and allows for quantitative
estimates of protein abundance [13]. Changes in specific protein
families or networks can be characterized as shown here for
proteins of the extracellular matrix (ECM) and their receptors.
The ECM is a key component of the microenvironment that is in
immediate contact with the tumor cells and is a critical source for
growth, survival, motility and angiogenic factors that significantly
affect tumor biology and progression. In addition, cell adhesion to
the ECM through integrins and other cell surface receptors
triggers intracellular signaling pathways that can regulate cell cycle
progression, migration and differentiation. While hepatic ECM
has been extensively studied in the context of liver fibrosis, little
attention has been given to the role of the ECM in the early steps
of hepatocarcinogenesis. Therefore, delineating and comparing
the liver proteome changes of ECM components in two mouse
models of liver cancer represents a unique and important
contribution to our understanding of the molecular mechanisms
of early hepatocarcinogenesis, and to ongoing efforts to identify
novel diagnostic and therapeutic targets.
Results
Tumor Development in the PDGFC Tg and Pten Null Mice
and Liver Proteome Profiling
The liver specific PDGFC Tg and Pten null mouse models
reproduce the steps of HCC development observed in humans
progressing from steatohepatitis and fibrosis to hepatocyte
dysplasia and tumorigenesis. These events are associated with
significant modification of the stroma and associated extracellular
matrix. Preceding tumor development, there is accumulation of
collagen fibers in the liver of these mice (Figure 1A). Steatosis is
also particularly pronounced in the Pten null liver as shown by the
accumulation of lipid droplets (Figure 1A). Interestingly, the
phenotypes of the tumors are different in these two models with
characteristics of HCC in the PDGFC Tg model and with mixed
cell characteristics of HCC and cholangiocarcinoma in the Pten
null mice (Figure 1B). Extensive mass spectrometry analysis
following a multi-dimensional protein separation strategy com-
posed of two-dimensional HPLC followed by SDS-PAGE was
applied as described [13] to livers collected from these two models
at the fibrosis and steatosis stage as well as on small HCCs. For
each sample group, livers from three or four mice were pooled. A
total of 10,707 protein isoforms, products of 8,278 individual genes
were identified with high confidence. For each identified protein,
protein abundance was calculated using the frequency of tandem
mass spectra assigned to that protein. We previously reported that
this label-free approach provides a good estimate of protein
abundance in liver [13].
Collagen Protein Identification and Quantification
Out of the 44 alpha chains of the murine collagen family, a
total of 26, corresponding to 16 collagen types, were identified:
COL1A1, COL1A2, COL2A1, COL3A1, COL4A1, COL4A2,
Author Summary
The microenvironment can have a profound influence on
cellular behavior and survival and on growth of developing
tumor cells. We present the first comprehensive analysis of
the extracellular matrix (ECM) and associated receptor
proteomes, applied here to the study of hepatocellular
carcinoma (HCC). This study demonstrates the utility of
mass spectrometry-based approaches to characterize, at
the protein level, gene families with extensive sequence
homology, post-transcriptional regulations, and post-
translational regulations. This is also the first study to
analyze and compare liver proteome changes occurring
during the transition from fibrosis and steatohepatitis,
common preneoplastic conditions in humans, to HCC,
using two mouse models. This approach identifies ECM
and integrin components, which could play an important
role in the early steps of hepatocarcinogenesis, and
provides a path to identifying ECM–tumor cell networks
that may contribute to the heterogeneous features of HCC.
Figure 1. Collagen deposition and tumor morphology in PDGFC Tg and Pten null liver. A) Masson’s trichrome stained liver sections
showing hepatic pericellular collagen deposition in 6-month-old PDGFC Tg and Pten null mice compared to WT littermates and control mice. Black
star: lipid droplets in Pten null livers; CV: central vein. B) H&E stained liver sections showing HCC formation in a 8-month-old PDGFC Tg mouse
detected by ultrasound, and HCC and CC formation in a 9-month-old Pten null mouse. Magnification: 6200.
doi:10.1371/journal.pgen.1002147.g001
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COL5A3, COL6A1, COL6A2, COL6A3, COL7A1, COL8A1,
COL10A1, COL14A1, COL15A1, COL16A1, COL18A1, CO-
L22A1, COL27A1, COL28A1 (Table 1). All 26 collagens were
identified with ProteinProphet scores of 0.97 or higher correspond-
ing to a false discovery rate of 0.003 and all 26 collagens were
identified in both mouse models. For 16 of these 26 collagens, this
study represents to date the first evidence at the protein level (www.
uniprot.org). The information on protein annotation, peptide
numbers and sequences is summarized in Table S1. As expected,
collagens types I and III were predominant in abundance. Among
theremainingcollagens,collagenstypesIV,V and VIwerethe most
abundant. Significant changes in abundance during disease
progression were observed for all 26 collagen proteins. In human
liver, type I and III collagen levels increase up to eight times during
fibrogenesis, with a significantly higher increase of type I collagen
than of type III collagen. Similarly, type I and III collagen levels
strongly increased in the fibrotic liver of 2-month-old PDGFC Tg
mice with a significantly higher increase of COL1A1 and COL1A2
than of COL3A1 (Figure 2A). Eight collagens of lower abundance
were also up-regulated in the PDGFC Tg fibrotic liver. These
included: COL2A1, COL5A1, COL5A2, COL5A3, COL8A1,
COL22A1, COL27A1 and COL28A1 (Figure 2B).
Collagen Protein Abundance Changes in Tumors
The protein abundance of the remaining 15 identified collagens
increased in the tumors of 8-month old PDGFC Tg mice as shown in
Figure 3A for the proteins of moderate to high abundance (COL4A1,
COL4A2, COL6A1, COL6A2, COL6A3, COL14A1 and CO-
L18A1) and in Figure 3B for the proteins of lower abundance
(COL4A3, COL4A4, COL4A5, COL4A6, COL7A1, COL10A1,
COL15A1 and COL16A1). The same abundance changes were
observed for these 15 collagens inthe tumors of 9-month old Pten null
mice (Figure 3C, 3D). In both models, the tumor-associated
abundance increase was particularly significant for collagens type
IV, VI, XIV, XV and XVI. Validation at the transcript level was
performed for Col4a2 and Col15a1. Col4a2 mRNA was strongly up-
regulated in tumors of both models with 10.8-foldincrease (p=0.008)
in PDGFC Tg mice (Figure 4A) and 4.8-fold increase (p=0.002) in
Pten null mice (Figure 4B). Col4a2 mRNA expression was also
significantly higher in tumors compared to adjacent tissue of both
models (p=0.01 in PDGFC Tg mice and p=0.001 in Pten null mice).
Col15a1 mRNA was not detected in control liver tissues and was only
weakly expressed in fibrotic and steatotic liver in both models. Its
expression was significantly increased in tumors in both models with
6.8-fold increase (p=0.009) in PDGFC Tg mice (Figure 4C) and 6.3-
foldincrease(p=0.003) in Ptennullmice(Figure4D).Col15a1mRNA
expression was also significantly higher in tumors compared to
adjacent tissue in both models (p=0.04 in PDGFC Tg mice and
p=0.02inPten null mice).
Collagen Post-Transcriptional Variants
Peptides specific to post-transcriptional variants were identified
for Col1a1, Col6a2, Col6a3 and Col18a1 (Figure 5). These variants
result from alternative splicing for Col1a1, Col6a2 and Col6a3 and
from alternative promoter usage for Col18a1. Validation at the
transcript level was performed for Col6a2 and Col18a1 using
primers specific to the post-transcriptional variants. Col6a2
canonical mRNA was strongly up-regulated in tissue adjacent to
tumors in both models with 23.4-fold increase (p=0.01) in PDGFC
Tg mice (Figure 6A) and 6.0-fold increase (p=0.02) in Pten null
mice (Figure 6B). A correlated up-regulation was observed for
Col6a2 splice variant with 8.5-fold increase (p=0.01) in PDGFC Tg
mice (Figure 6C) and 3.4-fold increase (p=0.02) in Pten null mice
(Figure 6D). Col18a1 canonical mRNA also called NC1-764, was
unchanged in liver tissue and tumors of PDGFC Tg mice
(Figure 7A) and decreased in tumors of Pten null mice (5.5-fold,
p=0.002) (Figure 7B). In contrast, Col18a1 variant NC1-301
strongly increased in tumors in both models with 32.8-fold
increase (p=0.01) in PDGFC Tg mice (Figure 7C) and 118.7-fold
increase (p=0.0006) in Pten null mice (Figure 7D). Col18a1 variant
NC1-301 also strongly increased in adjacent tissue in both models
with 16.9-fold increase (p=0.01) in PDGFC Tg mice (Figure 7C)
and 50.7-fold increase (p=0.001) in Pten null mice (Figure 7D).
Lysine Hydroxylation of Collagens
Lysine hydroxylation is a well-known post-translational modi-
fication of type I, III and V collagens and contributes to matrix
remodeling and stiffening. We investigated whether lysine
hydroxylation occurs on other collagens and changes in abun-
dance during tumor development, by researching the mass
spectrometry raw data using criteria allowing for the identification
of lysine hydroxylation modifications. Extensive lysine hydroxyl-
ation modification was observed as expected for COL1A1,
COL1A2, COL3A1 and COL5A1 with 9, 12, 7 and 5 modified
lysine residues identified, respectively. Other collagens with
modified lysine residues included all six type IV collagens,
COL6A2, COL16A1 and COL27A1 (Table 2). The lysine
Table 1. Collagen proteins identified in PDGFC Tg and Pten
null liver.
Protein names Gene names
# Unique
peptides
Collagen alpha-1(I) chain Col1a1 29
Collagen alpha-2(I) chain Col1a2*3 0
Collagen alpha-1(II) chain Col2a1 8
Collagen alpha-1(III) chain Col3a1*1 1
Collagen alpha-1(IV) chain Col4a1*1 1
Collagen alpha-2(IV) chain Col4a2*1 1
Collagen alpha-3(IV) chain Col4a3 4
Collagen alpha-4(IV) chain Col4a4*7
Collagen alpha-5(IV) chain Col4a5*3
Collagen alpha-6(IV) chain Col4a6*3
Collagen alpha-1(V) chain Col5a1*1 0
Collagen alpha-2(V) chain Col5a2 5
Collagen alpha-3(V) chain Col5a3*2
Collagen alpha-1(VI) chain Col6a1*1 7
Collagen alpha-2(VI) chain Col6a2*2 4
Collagen alpha-3(VI) chain Col6a3 67
Collagen alpha-1(VII) chain Col7a1*4
Collagen alpha-1(VIII) chain Col8a1 1
Collagen alpha-1(X) chain Col10a1*2
Collagen alpha-1(XIV) chain Col14a1*2 5
Collagen alpha-1(XV) chain Col15a1 7
Collagen alpha-1(XVI) chain Col16a1*6
Collagen alpha-1(XVIII) chain Col18a1 14
Putative protein COL22A1 Col22a1*5
Collagen alpha-1(XXVII) chain Col27a1 6
Collagen alpha-1(XXVIII) chain Col28a1 5
*No previous evidence at the protein level reported in UniProtKB (www.uniprot.
org).
doi:10.1371/journal.pgen.1002147.t001
Extracellular Matrix Proteome in Liver Cancer
PLoS Genetics | www.plosgenetics.org 3 June 2011 | Volume 7 | Issue 6 | e1002147hydroxylation status was particularly high for COL3A1 with 94%
of identified peptides presenting with lysine modifications in both
PDGFC Tg fibrotic liver and Pten null steatotic liver; and with
100% of identified peptides presenting with lysine modifications in
the tumors collected from both models (Figure 8). The lysyl
hydroxylation status of COL1A1 and COL1A2 also slightly
increased in the tumors compared to the fibrotic and steatotic
livers in both models increasing from 33% to 43% for COL1A1
and from 21% to 25% for COL1A2 in PDGFC Tg mice and
increasing from 27% to 37% for COL1A1 and from 15% to 17%
Figure 2. Collagen proteins up-regulated in PDGFC Tg fibrotic liver. The figure includes the collagens identified as up-regulated in PDGFC Tg
fibrotic liver compared to PDGFC Tg tumors and WT liver. For each protein, the abundance is shown as the total number of tandem mass spectra
assigned to that protein. The collagens of high abundance are shown in panel A and those of lower abundance are shown in panel B.
doi:10.1371/journal.pgen.1002147.g002
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hydroxylation status of COL6A2 slightly decreased in the tumors
compared to the fibrotic and steatotic livers in both models
decreasing from 29% to 17% in PDGFC Tg mice and from 15% to
13% in Pten null mice (Figure 8). For the type IV collagens, the
hydroxylation status was below 5%. Low hydroxylation was also
found for COL5A1, COL5A2, COL16A1 and COL27A1.
Non-Collagenous ECM Components
The ECM is also composed of non-collagenous proteins such as
laminins. Laminins are large macromolecules constituted by the
association of one a, one b and one c chain. Laminin a5, laminin
b2 and laminin c1 were up-regulated in the tumors of both mouse
models (Figure 9), suggesting that laminin 521 (previously called
laminin 11) is the most abundant laminin in HCC. Laminin b3
and laminin c2 were specifically up-regulated in Pten null tumors
while laminin b1 was specifically up-regulated in PDGFC Tg
tumors (Figure 9). Perlecan, also known as HSPG2, decorin and
nidogen 1 were up-regulated in tumors of both models. Validation
at the transcript level was performed for laminin a5 and nidogen
1. Laminin a5 mRNA was only weakly expressed in fibrotic and
steatotic liver in both models but was significantly up-regulated in
tumors in both models (6.4-fold (p=0.01) in PDGFC Tg mice and
10.5-fold (p=0.0002) in Pten null mice) (Figure 10). Laminin a5
mRNA expression was also significantly higher in tumors
compared to adjacent tissues, in both models (p=0.02 in PDGFC
Tg mice and p=0.03 in Pten null mice) (Figure 10). Nidogen 1
mRNA was increased by 7.2-fold (p=0.008) and by 8.9-fold
(p=0.0003) in tumors from PDGFC Tg and Pten null mice,
respectively (Figure 11A, 11B). Similarly, nidogen 1 protein was
increased by 6.1-fold (p=0.01) and by 15.3-fold (p=0.001) in
tumors from PDGFC Tg and Pten null mice, respectively
(Figure 11C, 11D).
PDGF Expression in Pten Null Mice
Because of the similarity in ECM composition in both models,
we investigated whether PDGF ligands were up-regulated in Pten
null liver. While Pdgfb mRNA was undetected, both Pdgfa and Pdgfc
Figure 3. Collagen proteins up-regulated in PDGFC Tg and Pten null tumors. A,B) The figure includes the collagens identified as up-
regulated in PDGFC Tg tumors compared to PDGFC Tg fibrotic and WT liver. C,D) The figure includes the collagens identified as up-regulated in Pten
null tumors compared to Pten null steatotic and control liver. For each protein, the abundance is shown as the total number of tandem mass spectra
assigned to that protein. The collagens of high abundance are shown in panels A and C and those of lower abundance are shown in panels B and D.
doi:10.1371/journal.pgen.1002147.g003
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(p=0.0007 and p=0.002, respectively) and in adjacent tissue by
2-fold (p=0.003 and p=0.02, respectively) (Figure 12). The up-
regulation of both PDGFA and PDGFC may therefore explain the
common ECM changes observed in the PDGFC Tg and Pten null
tumors and adjacent tissue.
ECM Receptors
Cell-ECM interactions are largely mediated through receptors
called integrins made up of a and b chains. While integrin a5 was
the most abundant and commonly up-regulated integrin chain in
the tumors of both mouse models, the pattern of the other
identified integrins was significantly different between the two
models (Figure 13). Integrins a2b, a3 and b1 were specific to Pten
null tumors while integrins a8 and b5 were specific to PDGFC Tg
tumors. The up-regulation of integrin a6 and of CD44 was also
much stronger in Pten null tumors compared to PDGFC Tg tumors.
The differential expression of integrins a6 and a8 was further
validated. Integrin a6 mRNA was increased by 39.0-fold
(p=0.001) in Pten null tumors and by 11.6-fold (p=0.002) in
PDGFC Tg tumors (Figure 14A, 14B). Integrin a8 mRNA was
increased in PDGFC Tg liver tissue at all disease stages by 16.2- to
24.0-fold (Figure 14C) but remained unchanged in Pten null liver
(Figure 14D).
In summary (Figure 15), this study identified collagens type IV,
VI, VII, X, XIV, XV, XVI and the short variant of COL18A1,
NC1-301, as tumor-associated collagens in HCC. Laminin 521
was the most abundant laminin in HCC and integrin a5 the most
abundant integrin subunit. High ratios of COL18A1 variant NC1-
301 over COL18A1 variant NC1-764, high ratios of integrin a6
over integrin a8 and high levels of integrin a3 were specifically
observed in the Pten null tumors.
Figure 4. Up-regulation of Col4a2 and Col15a1 mRNAs in PDGFC Tg and Pten null tumors. A,C) Expression of Col4a2 and Col15a1 mRNAs
was measured by quantitative PCR in PDGFC Tg fibrotic liver, in PDGFC Tg tumor and adjacent tissue, and in age-matched WT liver. B,D) Similarly,
expression of Col4a2 and Col15a1 mRNAs was measured in Pten null steatotic liver, in Pten null tumor and adjacent tissue, and in age-matched control
liver. Expression in the disease groups is represented as fold changes over the mean of expression in the control groups.
doi:10.1371/journal.pgen.1002147.g004
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The microenvironment can have profound influences on
cellular behavior, survival and growth of developing tumor cells
[14]. Increased rigidity of the ECM is commonly associated with
HCC [15] and ECM deposition and matrix remodeling has been
shown to affect liver progenitor cell expansion [16]. We
characterized and compared ECM protein changes occurring
during tumor development in the PDGFC Tg mouse model, a
model of HCC associated with fibrosis and angiogenesis [4] and in
the Pten null mouse model, a model of liver tumors of mixed
cholangio- and hepatocytic features [6–8,17]. This study repre-
sents the most comprehensive analysis of the ECM and associated
receptor proteome reported to date, and demonstrates the utility of
mass spectrometry-based approaches to study gene families with
extensive sequence homology, post-transcriptional and post-
translational regulations. It is also the first study to analyze and
compare proteome changes occurring during the transition from
fibrosis and steatosis to HCC in two mouse models.
Collagens, the most abundant structural components of the
ECM are homo- and heterotrimeric molecules whose subunits, the
alpha chains, are distinct gene products. Forty-four different alpha
chains have been sequenced, several of them being differentially
spliced, which adds to the diversity of the collagen family. To date,
28 different combinations of the alpha chains (collagen types I–
XXVIII) have been identified or predicted to exist (www.uniprot.
org). While only ten collagen types have been described in the liver
[15], this extensive proteomic study resulted in the identification of
16 types. Fibril-forming types I and III collagens are predomi-
nantly synthesized by hepatic stellate cells and are used as markers
for liver fibrogenesis. In the fibrotic liver of PDGFC Tg mice, type I
and III collagen levels strongly increased with a significantly
higher increase of type I collagen than of type III collagen
changing the I/III ratio from 1:1 in the healthy liver to over 2:1, as
observed in human fibrotic liver. Collagens type V (COL5A1,
COL5A2 and COL5A3) and type II (COL2A1), the other fibril-
forming collagens, were also up-regulated in the fibrotic liver of
the PDGFC Tg mice. This ECM composition in the fibrotic liver of
PDGFC Tg mice is consistent with a signature of activated hepatic
stellate cells, a hallmark of PDGFC Tg mice [4]. Out of the 26
alpha chains identified, 15 were up-regulated in tumors of both
models. These include the six alpha chains of collagen IV, the
three alpha chains of collagen VI, COL7A1, COL10A1,
COL14A1, COL15A1, COL16A1 and COL18A1. Collagen VI,
a component of microfibrillar structures in many tissues, is a
heterotrimer with the chain composition (6a1)(6a2)(6a3). Type VI
collagen binds cells and may be involved in cell migration and
differentiation and embryonic development. All collagen VI
subunits, including splice variants for COL6A2 and COL6A3,
were up-regulated in the tumors and adjacent tissue of both
models. The most abundant structural component of basement
membranes is collagen IV. The six different alpha chains 4a1–4a6
were up-regulated in the tumors of both mouse models. Besides
the heterotrimeric molecule (4a1)2(4a2) composed of the two most
Figure 5. Identification of peptides specific to post-transcriptional variants for Col1a1, Col6a2, Col6a3, and Col18a1. The figure shows
the exon structures of post-transcriptional variants for Col1a1, Col6a2, Col6a3 and Col18a1 and the associated specific peptides identified by mass
spectrometry in the PDGFC Tg and Pten null liver.
doi:10.1371/journal.pgen.1002147.g005
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alpha chains, particularly those including the subunits of minor
abundance, are not yet established. Whereas COL4A1 and
COL4A2 are found in all basement membranes studied,
COL4A3, COL4A4 and COL4A5 are found only in a subset of
basement membranes and are always found together [18]. Strong
deposition of collagen type IV was described in dysplastic areas
and small HCCs in human cirrhotic livers indicative of early
events in hepatocarcinogenesis [19]. The multiplexin collagens
XV and XVIII are also localized to basement membranes.
COL15A1 was the collagen alpha chain that showed the stronger
up-regulation in both the Pten null and PDGFC Tg tumors.
COL18A1 was also up-regulated in the mice tumors. Interest-
ingly, increases in this protein correlated with the increase of a
specific isoform of Col18a1 mRNA, isoform NC1-301, resulting
from alternative promoter usage. NC1-301 mRNA was increased
by over 30-fold in PDGFC Tg tumors and over 100-fold in Pten null
tumors. In contrast, the canonical Col18a1 mRNA, NC1-764, was
unchanged or slightly decreased in the PDGFC Tg tumors and
strongly decreased in Pten null tumors. It was previously reported
that NC1-764 mRNA expression decreases in advanced HCCs
[20] and that cholangiocarcinoma cells expressed NC1-301 which
was deposited in tumor basement membrane [21]. This is in good
agreement with the changes we observed in both COL18A1
isoforms in the mice tumors, with a greater ratio NC1-301/NC1-
764 in Pten null tumors compared to PDGFC Tg tumors. These
results suggest that the ratio of COL18A1 isoforms could directly
correlate with the expansion of intermediate cells co-expressing
both hepatocytes and biliary markers. Finally, collagen VII, the
main constituent of anchoring fibrils, was also up-regulated in
tumors of both models. It has been reported that human epidermal
cells devoid of collagen VII did not form tumors in mice, whereas
those retaining the specific N-terminal NC1 domain were
tumorigenic [22].
Figure 6. Expression of Col6a2 mRNA variants upon disease progression in PDGFC Tg and Pten null liver. A,C) Expression of Col6a2
mRNA splice variants was measured by quantitative PCR in PDGFC Tg fibrotic liver, in PDGFC Tg tumor and adjacent tissue and in age-matched WT
liver. B,D) Similarly, expression of Col6a2 mRNA splice variants was measured in Pten null steatotic liver, in Pten null tumor and adjacent tissue and in
age-matched control liver. Expression in the disease groups is represented as fold changes over the mean of expression in the control groups.
doi:10.1371/journal.pgen.1002147.g006
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and nidogen 1 increased in the mice tumors. Nidogens are
believed to connect laminin and collagen IV networks, hence
stabilizing the basement membrane structure and appear critical
for anchoring other components such as perlecan. At present, five
laminin a (a1–a5), three b (b1–b3) and three c (c1–c3) chains and
16 trimers have been characterized in mouse and human [23].
Based on the chain identification, laminins 511 or 521 (previously
called laminin 10/11) and laminin 522 are likely up-regulated in
PDGFC Tg and Pten null tumors. It was reported that laminins
containing the a5 chain serve as functional regulators of HCC
progression [24]. Up-regulation of laminin b3, a major component
of laminin 332 (previously called laminin 5) was observed
specifically in Pten null tumors. Interestingly, laminin b3 was
reported up-regulated in cholangiocarcinoma cell lines compared
to HCC cell lines [25] and laminin 332 is present in almost all
intrahepatic cholangiocarcinoma cases [26].
The global expression of the ECM in liver during tumor
development results from the combined expression profiles of
tumor cells, stromal cells, and non-tumor hepatocytes. Activated
hepatic stellate cells and myofibroblasts express a wide spectrum of
ECM molecules but an important fraction of ECM is also
synthesized by other liver cells, notably sinusoidal and portal
endothelia, bile duct epithelia and hepatocytes [27,28]. While this
study increases our knowledge of HCC-specific matrix composi-
tion, future studies should focus on the cellular distribution of the
described proteins. Overall, beside a subset of laminins, the ECM
changes were remarkably similar in the tumors and adjacent
tissues of both mouse models, suggesting a common molecular and
cellular mechanism. We therefore investigated the possibility that
Figure 7. Expression of Col18a1 mRNA variants upon disease progression in PDGFC Tg and Pten null liver. A,C) Expression of Col18a1
mRNA variants NC1-764 and NC1-301 was measured by quantitative PCR in PDGFC Tg fibrotic liver, in PDGFC Tg tumor and adjacent tissue and in
age-matched WT liver. B,D) Similarly, expression of Col18a1 mRNA variants NC1-764 and NC1-301 was measured in Pten null steatotic liver, in Pten null
tumor and adjacent tissue and in age-matched control liver. Expression in the disease groups is represented as fold changes over the mean of
expression in the control groups.
doi:10.1371/journal.pgen.1002147.g007
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mRNA was undetected in Pten null liver, both Pdgfa and Pdgfc
transcripts were increased in Pten null tumors and adjacent tissues.
We also observed an up-regulation of both PDGF receptor alpha
and PDGF receptor beta in Pten null tumors and adjacent tissues
(LB, personal communication).
Most cell types have the ability to bind to the surrounding ECM
and certain ECM components can transmit signals to cells via
transmembrane receptors [29]. Such matrix sensors are mainly
integrins. Integrins comprise a large family of cell surface
glycoproteins which consist of alpha and beta subunits and that
regulate cell adhesion, migration, proliferation and apoptosis [30].
There are 18 a and 8 b subunits, each of which can bind to several
partners giving rise to at least 24 distinct integrin heterodimers
with different functions and ligand binding activities. Laminins are
ligands for both a6b1 and a3b1 integrins. These integrins were
specifically up-regulated in Pten null tumors. Interestingly, laminin
511 modulates human embryonic stem cell aggregation and
adherence through binding of the a6b1 integrin receptor highly
expressed in the membranes of undifferentiated stem cells [31,32].
It was also reported that oval cells express integrin a6 [33].
Similarly, laminin 332 and integrin a3 were co-up-regulated in
Pten null tumors. It was reported that cells lacking integrin a3d o
not proliferate in response to laminin 332 treatment [34].
Altogether, these results suggest that laminin 332/integrin a3–
induced HCC growth and that laminin 511-integrin a6b1
interaction is specific to Pten null tumors.
T h ei d e n t i f i e dH C C – a s s o c i a t e dE C Ma n di n t e g r i nc o m p o n e n t s
could play an important role in the promotion of the early steps of
hepatocarcinogenesis, providing a foundation for novel strategies to
Table 2. Collagens with lysine hydroxylation modifications identified in PDGFC Tg and Pten null liver.
Protein names Gene names # sites Lysine residues
Collagen alpha-1(I) chain Col1a1 9 K(160), K(266), K(386), K(419), K(437), K(457), K(541), K(575), K(1085)
Collagen alpha-2(I) chain Col1a2 12 K(360), K(366), K(386), K(504), K(512), K(744), K(747), K(750), K(753), K(852),
K(1014), K(1020)
Collagen alpha-1(III) chain Col3a1 7 K(502), K(742), K(756), K(823), K(859)*, K(1030), K(1149)
Collagen alpha-1(IV) chain Col4a1 1 K(1651)
Collagen alpha-2(IV) chain Col4a2 2 K(165), K(932)
Collagen alpha-3(IV) chain Col4a3 1 K(90)
Collagen alpha-4(IV) chain Col4a4 1 K(1400)
Collagen alpha-5(IV) chain Col4a5 2 K(664), K(1008)
Collagen alpha-6(IV) chain Col4a6 1 K(790)
Collagen alpha-1(V) chain Col5a1 5 K(535), K(905), K(963), K(1433), K(1792)
Collagen alpha-2(V) chain Col5a2 1 K(584)
Collagen alpha-2(VI) chain Col6a2 2 K(408), K(500)
Collagen alpha-1(XVI) chain Col16a1 2 K(496), K(683)
Collagen alpha-1(XXVII) chain Col27a1 2 K(202), K(1477)
doi:10.1371/journal.pgen.1002147.t002
Figure 8. Percentage of peptides with lysine hydroxylation identified for COL1A1, COL1A2, COL3A1, and COL6A2. In A) PDGFC Tg
fibrotic (F) and tumors (T) and in B) Pten null steatotic liver (S) and tumors (T).
doi:10.1371/journal.pgen.1002147.g008
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components or blocking their interactions with signaling integrins
could serve as a means for establishing a non-permissive microen-
vironment that may prevent tumor development. Integrin inhibitors
such as humanized antibodies or blocking peptides against integrin
a5b1 are currently under clinical investigation. Our results suggest
that these novel drugs should be evaluated for the treatment of HCC.
In addition, integrin a3b1-laminin 332 and integrin a6b1-laminin
511 networks may be promising targets to prevent laminin-tumor cell
interaction in HCC with dysregulated PTEN function.
Figure 9. Non-collagenous ECM proteins up-regulated in PDGFC Tg and Pten null tumors. A) The figure includes the non-collagenous ECM
proteins identified as up-regulated in PDGFC Tg tumors compared to PDGFC Tg fibrotic liver. B) The figure includes the non-collagenous ECM proteins
identified as up-regulated in Pten null tumors compared to Pten null steatotic liver. For each protein, the abundance is shown as the total number of
tandem mass spectra assigned to that protein.
doi:10.1371/journal.pgen.1002147.g009
Figure 10. Up-regulation of laminin a5 mRNA in PDGFC Tg and Pten null tumors. A) Expression of laminin a5( Lama5) mRNA was measured
by quantitative PCR in PDGFC Tg fibrotic liver, in PDGFC Tg tumor and adjacent tissue, and in age-matched WT liver. B) Similarly, expression of laminin
a5( Lama5) mRNA was measured in Pten null steatotic liver, in Pten null tumor and adjacent tissue, and in age-matched control liver. Expression in the
disease groups is represented as fold changes over the mean of expression in the control groups.
doi:10.1371/journal.pgen.1002147.g010
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Mouse Samples
The PDGFC Tgmiceused for this studywere previously described
[4]. Liver tissue samples were collected by necropsy from 1.5-month
old PDGFC Tg mice with hepatic fibrosis, 8-month old PDGFC Tg
mice with small HCCs and from 1.5-month and 8-month old wild-
type controls. Mice carrying Pten conditional knockout alleles were
crossed with an Albumin (Alb)-Cre-transgenic mouse. The Alb-Cre-
transgenic mice were genotyped using Cre specific primers. For this
model, control animals are Pten
loxP/loxP; Alb-Cre
2. Liver tissue samples
were collected by necropsy from 6-month old Pten null mice with
steatosis, 9-month old Pten null mice with small HCCs and from 6-
month and 9-month old control mice. All tissues were immediately
snap-frozen in liquid nitrogen or fixed in 10% neutral buffered
formalin overnight, processed to paraffin blocks, sectioned, and
stained with hematoxylin/eosin or Masson’s trichrome by using
standard techniques. This study was carried out in strict accordance
with the regulations of the U.S. National Institutes of Health. All of
the workwithanimalswasperformed inadherencetothe ‘‘Guidefor
the Care and Use of Laboratory Animals’’ published by the U.S.
National Research Council, including the use of appropriate
anesthesia whenever recommended by these guidelines. The
protocol was approved and reviewed annually by the Institutional
Animal Care and Use Committee of the Fred Hutchinson Cancer
Research Center (File #1662). Every effort was made to minimize
the number of animals required for the study and to minimize the
pain and discomfort experienced.
Protein Extraction and Separation
Liver tissues from three or four mice in each study group were
separately ground on dry ice and subsequently pooled. Proteins
were extracted twice from 40 mg of each pooled group in 1 ml
lysis buffer (5 M urea, 2 M thiourea, 2% w/v n-Octyl-b-D-
Figure 11. Up-regulation of nidogen 1 mRNA and protein in PDGFC Tg and Pten null tumors. A,C) Expression of nidogen 1 mRNA and
protein was measured by quantitative PCR and Western-blot, in PDGFC Tg fibrotic liver, in PDGFC Tg tumor and adjacent tissue and in age-matched
WT liver. B,D) Similarly, expression of nidogen 1 mRNA and protein was measured in Pten null steatotic liver, in Pten null tumor and adjacent tissue,
and in age-matched control liver. Expression in the disease groups is represented as fold changes over the mean of expression in the control groups.
doi:10.1371/journal.pgen.1002147.g011
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fluoride). Following centrifugation at 16,1006ga t4 uCf o r1h r ,
the pellet fraction was solubilized in Laemmli buffer and the
proteins from the supernatant were separated using the Alliance
2-D Bioseparations System (Waters Corporation, Milford, MA)
as previously described [13]. Briefly, an anion exchange column,
BioSuite Q 10 mm, (Waters Corporation, Milford, MA) was used
for the first dimension. Eight stepwise gradients were performed
consisting of 0, 100 mM, 200 mM, 350 mM, 500 mM, 650 mM,
800 mM and 1000 mM NaCl. The reversed phase columns,
Symmetry300 C4 3.5 mm, (Waters Corporation, Milford, MA)
were used for separation of the fractions obtained from the first
Figure 12. Up-regulation of Pdgfa and Pdgfc mRNAs in Pten null tumors. Expression of A) Pdgfa mRNA and B) Pdgfc mRNA was measured in
Pten null steatotic liver, in Pten null tumor and adjacent tissue, and in age-matched control liver. Expression in the disease groups is represented as
fold changes over the mean of expression in the control groups.
doi:10.1371/journal.pgen.1002147.g012
Figure 13. CD44 and integrin proteins up-regulated in PDGFC Tg and Pten null tumors. A) The figure includes CD44 and the integrin
subunits identified up-regulated in PDGFC Tg tumors compared to PDGFC Tg fibrotic liver. B) The figure includes CD44 and the integrin subunits
identified as up-regulated in Pten null tumors compared to Pten null steatotic liver. For each protein, the abundance is shown as the total number of
tandem mass spectra assigned to that protein.
doi:10.1371/journal.pgen.1002147.g013
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through the column selector. A total of ,260 fractions was
collected for each pooled group. Some adjacent fractions were
combined leading to a final number of 34 samples for each
pooled group. All fractions were lyophilized and resuspended in
Laemmli buffer. Proteins obtained from the 2-D HPLC
separations were further separated by 12% SDS PAGE. Gel
pieces were combined into 37 individual samples for each pooled
group according to protein size and abundance, dehydrated with
100% acetonitrile and dried using a speed vacuum. Gel pieces
were incubated with 10 ml of 6.7 ng/ml trypsin in digestion buffer
overnight at 37uC. The reaction was stopped with 15 mlo f
extraction buffer (2% formic acid/3% acetonitrile) and the
supernatants were collected.
Mass Spectrometry
The generated peptide samples were desalted using Symme-
try C18 de-salting columns (Waters Corporation, Milford, MA)
and subjected in duplicate to nanoflow LC-MS/MS analysis
with a nano-UPLC system (Waters Corporation, Milford, MA)
coupled to a hybrid 7-Tesla linear ion-trap Fourier-transform
ion cyclotron resonance mass spectrometer (LTQ-FT, Thermo
Scientific, Waltham, MA). Peptides were separated on a
reversed phase column (75 mm6250 mm) packed with Magic
C18AQ (5-mm 100 A ˚ resin; Michrom Bioresources, Auburn,
CA) and directly mounted on the electrospray ion source. We
used a 60 min gradient from 10% to 40% acetonitrile in 0.1%
formic acid at a flow rate of 300 nl/min. A spray voltage of
1600 V was applied. The LTQ-FT instrument was operated in
the data-dependent mode, switching automatically between MS
survey scans in the FTICR (target value 1,600,000, resolution
100,000, and injection time 1.5 s) with MS/MS spectra
acquisition in the linear ion trap. The five most intense ions
from the FT full scan were selected for fragmentation in the
linear ion trap by collision-induced dissociation with a
normalized collision energy of 30% at a target value of 10,000
Figure 14. Expression of integrin a6 and a8 mRNAs upon disease progression in PDGFC Tg and Pten null liver. A,C) Expression of Itga6
and Itga8 mRNAs was measured by quantitative PCR in PDGFC Tg fibrotic liver, in PDGFC Tg tumor and adjacent tissue, and in age-matched WT liver.
B,D) Similarly, expression of Itga6 and Itga8 mRNAs was measured in Pten null steatotic liver, in Pten null tumor and adjacent tissue, and in age-
matched control liver. Expression in the disease groups is represented as fold changes over the mean of expression in the control groups.
doi:10.1371/journal.pgen.1002147.g014
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excluded for 60 s. The absolute average mass accuracy for the
parent ion was ,5p p m .
Proteomic Data Analysis
Acquired data were processed using the X!Tandem search
algorithm [35] and PeptideProphet and ProteinProphet statis-
tical tools [36,37]. The tandem mass spectra were searched
against the mouse International Protein Index protein sequence
database (IPI, version 3.34, http://www.ebi.ac.uk/IPI/). The
following search criteria were used in all cases: trypsin
specificity, 2.5 Da of mass accuracy for the parent ion and
methionine oxidation as a variable modification and when
specified, lysine oxidation was added as a variable modification.
Relative abundance scores were calculated for individual
proteins based on total peptide counts normalized to account
for the total amount of protein in the mixture.
Quantitative PCR
Total RNA was extracted from individual liver tissue samples
and purified using the Trizol reagent (Invitrogen, Carlsbad, CA).
RNA samples were then submitted to DNAse digestion, reverse
transcription using random hexamers and real-time PCR using
specific primers listed in Table S2. For each sample, the cDNA
equivalent to 1 ug total RNA per 20 ml reaction was amplified
with the iCycler MyiQ using SYBR Green Supermix and analyzed
by MyiQ software (Bio-Rad Laboratories, Hercules, CA) and
relative quantification of RNA expression was calculated with the
2
2DDCt method. Actin quantification was used for normalization.
The specificity of qPCR products was confirmed by melting curve
analysis and gel-based analysis of the PCR products.
Western Blotting
Proteins from individual liver tissues were extracted from
100 mg of liver, in 1 ml lysis buffer consisting of 5 M urea, 2 M
thiourea, 2% w/v n-Octyl-b-D-Glucopyranoside (Sigma-Aldrich,
St Louis, MO), 50 mM Tris (Fisher Scientific) and 1 mM
phenylmethylsulfonyl fluoride (GE Healthcare, Little Chalfont,
UK). The homogenate was centrifuged at 19,0006 ga t4 uC for
1 hour and supernatant was collected. Proteins (40 ug) were
loaded onto 12% SDS PAGE gels and immunoblotting was
performed using rat monoclonal anti-Nidogen 1 antibody (Santa
Cruz Biotechnology, Santa Cruz, CA) at 1/100 dilution.
Figure 15. Schema summarizing the ECM protein components and their receptors identified as up-regulated in PDGFC Tg and Pten
null tumors. All ECM proteins and associated receptors identified as up-regulated in the mice tumors are shown as follows: in black for collagens, in
blue for non-collagenous ECM proteins and in red for ECM receptors. Their position in the graph indicates whether they were commonly identified in
the tumors of both mouse models (overlapping section between the light green oval representing the Pten null tumors and the light blue square
representing the PDGFC Tg tumors) or identified specifically in one tumor type (light green section for Pten null tumors and light blue section for
PDGFC Tg tumors). These two latter non-overlapping sections of the graph also indicate ratios of selected proteins that may have utility in
discriminating between the PDGFC Tg and the Pten null tumors. The proteins in bold are those identified with higher abundance.
doi:10.1371/journal.pgen.1002147.g015
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using ECL kit (GE Healthcare, Little Chalfont, UK) and
quantification was performed using ImageJ (http://rsbweb.nih.
gov/ij/).
Supporting Information
Table S1 Collagen proteins, non-collagenous ECM proteins and
ECM receptors identified in PDGFC Tg and Pten null liver. The
table includes for each protein: the protein and gene names, IPI and
SwissProtaccessionnumbers,the ProteinProphet score,thenumber
and sequence of the unique peptides assigned to the protein.
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